Stocks Health care SYRE
NASDAQ · Health careSpyre Therapeutics, Inc. (SYRE)
It posted a net loss of $263.9M. At September 30, 2026 it held $82.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Spyre Therapeutics, Inc.
- Net worth
- Spyre Therapeutics, Inc. has a market value (market cap) of $9.2B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $155.2M.
- Cash flow
- In fiscal 2025 operations used $169.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Spyre Therapeutics, Inc.'s next report is expected around February 18, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Spyre Therapeutics, Inc. does
Spyre Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SYRE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$155.2M | n/a | n/a |
| 2024 | $0 | -$208M | n/a | -$157.4M |
| 2023 | $886K | -$338.8M | $13.76 | -$99.9M |
| 2022 | $2.3M | -$83.8M | -$24.86 | -$80.2M |
| 2021 | $18.7M | -$65.8M | -$25.02 | -$54.3M |
| 2020 | $0 | -$80.9M | -$38.03 | -$80.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Spyre Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026
- November 3, 2026
- October 9, 2026Activist stake changed SCHEDULE 13D/A
- October 7, 2026Material agreement8-KSpyre Therapeutics agreed to sell common stock in a public offering to raise approximately $350.0 million in gross proceeds.
- October 1, 2026Passive stake (5% or more) SCHEDULE 13G
- September 8, 2026
- August 25, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026
Insider trades
What the people running Spyre Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $12.3M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Burrows Scott LChief Financial Officer | Exercised options | 7,500 | $108.8K |
| October 1, 2026 | Burrows Scott LChief Financial Officer | Soldpre-planned (10b5-1) | 600 | $53.4K |
| October 1, 2026 | Burrows Scott LChief Financial Officer | Soldpre-planned (10b5-1) | 1,500 | $135.4K |
| October 1, 2026 | Burrows Scott LChief Financial Officer | Soldpre-planned (10b5-1) | 2,100 | $193K |
| October 1, 2026 | Burrows Scott LChief Financial Officer | Soldpre-planned (10b5-1) | 3,071 | $285.4K |
| October 1, 2026 | Burrows Scott LChief Financial Officer | Soldpre-planned (10b5-1) | 229 | $21.4K |
| October 1, 2026 | Turtle CameronChief Executive Officer, Director | Soldpre-planned (10b5-1) | 600 | $53.5K |
| October 1, 2026 | Turtle CameronChief Executive Officer, Director | Soldpre-planned (10b5-1) | 2,683 | $241.7K |
Who owns SYRE
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Peter Harwin13D, may seek influence with 3 related filers | 11.17% | April 25, 2024 |
| Fairmount Funds Management LLC13D, may seek influence with 5 related filers | 10.59% | December 11, 2023 |
| Harwin Peter Evan13D, may seek influence with 3 related filers | 9.99% | October 9, 2026 |
| Paradigm BioCapital Advisors LP13G, passive with 3 related filers | 5.1% | October 1, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 265 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 13,026,187 | +1,245,163 |
| BlackRock, Inc. | 6,506,605 | +985,384 |
| Perceptive Advisors LLC | 4,319,496 | +536,271 |
| Rtw Investments, LP | 4,251,996 | +80,000 |
| Paradigm Biocapital Advisors LP | 3,840,778 | +1,883,512 |
| Vanguard Capital Management LLC | 3,448,681 | +391,280 |
| State Street Corp | 3,057,416 | +450,385 |
| Venrock Adviser, LLC | 2,985,448 | -700,000 |
| Driehaus Capital Management LLC | 2,799,166 | +8,381 |
| Geode Capital Management, LLC | 2,562,265 | +841,353 |
| Vanguard Portfolio Management LLC | 2,330,098 | +1,744,968 |
| Capital World Investors | 2,315,553 | +1,648,989 |
| Jupiter Topco LLC | 2,206,936 | new |
| TCG Crossover Management, LLC | 1,900,582 | 0 |
| Tang Capital Management LLC | 1,892,200 | 0 |
| Bank of America Corp | 1,777,854 | +549,761 |
| Adage Capital Partners GP, L.L.C. | 1,722,300 | new |
| Wellington Management Group Llp | 1,581,505 | -243,306 |
| Goldman Sachs Group Inc | 1,478,059 | +1,208,121 |
| Franklin Resources Inc | 1,472,943 | +590,110 |
Insiders
5 insiders reported holding 698,113 shares in total, about $72.9M at the last price.
| Holder | Shares |
|---|---|
| Turtle CameronChief Executive Officer, Director | 537,540 |
| Burrows Scott LChief Financial Officer | 79,762 |
| Henderson Michael ThomasDirector | 68,606 |
| Albers Jeffrey W.Director | 9,3609,360 held indirectly |
| King-Jones HeidySee Remarks | 2,845 |
Questions about SYRE
What does Spyre Therapeutics, Inc. do?
Spyre Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as SYRE. Its shares trade on NASDAQ under the ticker SYRE.
What is Spyre Therapeutics, Inc.'s net worth?
Spyre Therapeutics, Inc. has a market value (market cap) of $9.2B at the latest share price, and shareholders' equity of $1.1B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Spyre Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $263.9M.
When did Spyre Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026.
When is Spyre Therapeutics, Inc.'s next earnings report?
Spyre Therapeutics, Inc.'s next report is expected around February 18, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare SYRE with
Follow SYRE
Get an email when Spyre Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Spyre Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.